10-Q: Tempest Therapeutics Q2 2025: Strategic Review & Pipeline Progress

Tempest Therapeutics reports Q2 2025 financial results, highlighting ongoing strategic review, workforce reduction, and progress in its clinical-stage oncology pipeline despite significant operating losses and going concern doubts.

Summary

• Net loss for Q2 2025 was $7.87 million, an 18% decrease from $9.57 million in Q2 2024.
• Net loss for the six months ended June 30, 2025, was $18.73 million, an increase from $17.47 million in the same period of 2024.
• Cash and cash equivalents decreased to $14.28 million as of June 30, 2025, from $30.27 million at December 31, 2024.
• Accumulated deficit reached $225.84 million as of June 30, 2025.
• The company is exploring strategic alternatives, including mergers, acquisitions, partnerships, and licensing arrangements, to maximize stockholder value.
• A workforce reduction of 21 out of 26 full-time employees was implemented by April 30, 2025, incurring $3.2 million in one-time severance costs.
• Key executives, including the CEO, CMO, and CFO, transitioned to consulting arrangements on June 5, 2025, while continuing in their roles.
• A 1-for-13 reverse stock split was effected on April 8, 2025.
• A $3.5 million loan to Oxford Finance LLC was fully repaid on April 8, 2025.
• A registered direct offering on June 11, 2025, raised approximately $4.1 million in net proceeds.
• Amezalpat (TPST-1120) received positive FDA feedback for its pivotal Phase 3 trial design in first-line HCC, along with Fast Track and Orphan Drug Designations from the FDA and Orphan Drug Designation from the EMA.
• TPST-1495 is expected to begin a Phase 2 study in Familial Adenomatous Polyposis (FAP) in 2025, having received Orphan Drug Designation from the FDA.

Sentiment

Score: 3

Explanation: While there are positive clinical and regulatory milestones for its drug candidates, the severe liquidity issues, explicit going concern doubt, and significant workforce reduction overshadow these positives, indicating a precarious financial position that could halt progress.

Positives

• Net loss decreased by 18% in Q2 2025 compared to Q2 2024, from $9.57 million to $7.87 million.
• Successful repayment of the $3.5 million loan to Oxford Finance LLC, terminating all associated liens and security interests.
• Successful completion of a registered direct offering, raising approximately $4.1 million in net proceeds.
• Positive survival data from the Phase 1b/2 clinical study of amezalpat in first-line HCC, showing a six-month improvement in median overall survival (HR 0.65).
• FDA provided positive feedback on the pivotal Phase 3 clinical trial design for amezalpat in HCC, including agreement on a pre-specified early efficacy analysis.
• Amezalpat received Fast Track Designation and Orphan Drug Designation from the FDA, and Orphan Drug Designation from the EMA, potentially accelerating development and providing market exclusivity.
• TPST-1495 is advancing to a Phase 2 study in Familial Adenomatous Polyposis (FAP) with NCI funding and received Orphan Drug Designation from the FDA.
• The company is actively exploring strategic alternatives to maximize stockholder value and extend financial resources.

Negatives

• Substantial doubt exists regarding the company's ability to continue as a going concern for the next 12 months due to finite cash resources and ongoing operating losses.
• Cash and cash equivalents significantly decreased to $14.28 million as of June 30, 2025, from $30.27 million at December 31, 2024.
• Accumulated deficit increased to $225.84 million as of June 30, 2025.
• Cash used in operating activities increased to $16.47 million for the six months ended June 30, 2025, from $12.70 million in the same period of 2024, despite cost reduction efforts.
• A workforce reduction of 21 out of 26 full-time employees was implemented, incurring $3.2 million in one-time severance costs.
• Research and development expenses increased by $1.3 million to $11.5 million for the six months ended June 30, 2025, primarily due to preparation for the pivotal Phase 3 trial of amezalpat, despite overall cost reduction efforts.
• The ATM program prospectus supplement was suspended and terminated, limiting immediate access to capital through this mechanism.

Risks

• Substantial doubt regarding the ability to continue as a going concern, requiring significant additional funding that may not be available on acceptable terms.
• Activities to evaluate strategic alternatives may not result in any transaction or enhance stockholder value, potentially leading to a wind-down of operations and total loss of investment.
• History of operating losses and anticipated continued losses for the foreseeable future, requiring additional funding to conduct planned research and development.
• Recently implemented corporate restructuring (workforce reduction) may not yield expected benefits and could lead to loss of institutional knowledge, decreased morale, or inability to distribute duties.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing proprietary rights.
• Inability to develop, obtain regulatory approval for, and commercialize product candidates (amezalpat, TPST-1495, or future candidates) or significant delays in doing so.
• Success in preclinical studies and earlier clinical trials may not be indicative of results in later clinical trials, potentially delaying or preventing regulatory approval.
• Inability to expand the pipeline of product candidates and develop marketable products.
• Commercial success depends on market acceptance by providers, patients, payors, and the medical community.
• Reliance on third parties for manufacturing clinical product supplies and potential commercial production.
• Significant competition in a rapidly changing technological environment, with competitors potentially achieving regulatory approval sooner or developing more effective therapies.
• Inability to establish sales and marketing capabilities or enter into agreements with third parties for marketing and sales.
• Lengthy and time-consuming FDA regulatory approval process, with potential for significant delays.
• Inability to obtain, maintain, and protect intellectual property rights, which is difficult and costly.
• Owned and in-licensed patents and patent applications may not provide sufficient protection or competitive advantage.
• The trading price of common stock has been and is likely to continue to be volatile, potentially leading to substantial losses for purchasers.
• The reverse stock split may reduce and limit market trading liquidity and potentially have an anti-takeover effect.
• Unstable market and economic conditions (inflation, volatility, geopolitical tensions) may adversely affect business, financial condition, and share price.
• Thinly traded common stock, making it difficult for stockholders to sell shares quickly or at market price.
• Failure to maintain proper and effective internal controls could impair the ability to produce accurate financial statements.
• Significant risk of product liability, with potential for insufficient insurance coverage.
• Provisions in the certificate of incorporation and by-laws and under Delaware law could make an acquisition more difficult.
• No anticipated cash dividends in the foreseeable future.
• Equity research analysts' reports could negatively impact stock price and trading volume.
• Stringent and evolving U.S. and foreign laws, regulations, and rules related to data privacy and security, with potential for non-compliance to harm business.
• Risk of misconduct or improper activities by employees, principal investigators, CROs, CMOs, and consultants.
• Difficulty obtaining regulatory approval in international jurisdictions.
• Subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations.
• Failure to comply with environmental, health, and safety laws and regulations.
• Changes in tax laws or regulations (e.g., OBBBA, IRA) could adversely affect the company.
• FDA's ability to review and approve new products may be hindered by various factors, including budget and funding levels.
• Adverse effects from natural disasters and other calamities, including public health crises, with potentially inadequate business continuity plans.

Future Outlook

The company expects its existing cash and cash equivalents to fund projected operating expenses for less than 12 months from the financial statement issuance date. It is actively exploring strategic alternatives, including mergers, acquisitions, partnerships, joint ventures, and licensing arrangements, to maximize stockholder value and extend financial resources. Amezalpat is poised to begin a pivotal Phase 3 study in first-line HCC, subject to additional resources, and TPST-1495 is expected to start a Phase 2 study in FAP in 2025.

Management Comments

• "We are a clinical-stage biotechnology company moving into late-stage development with a diverse portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class treatments for a wide range of cancers."
• "Our philosophy is to build a company based upon not only good ideas and creative science, but also upon the efficient translation of those ideas into therapies that will improve patients lives."
• "Given market conditions, in April 2025, we announced plans to explore a full range of strategic alternatives to advance our promising programs."
• "We have not set a timetable for completion of the process for evaluating strategic alternatives and do not intend to disclose further developments or guidance on the status of our programs or the process for evaluating strategic alternatives unless and until it is determined that further disclosure is appropriate or necessary."
• "If a strategic alternative is not available to us, we will be required to take additional actions to fund the Companys operations or we may be forced to wind down our operations."

Industry Context

Tempest Therapeutics operates in the highly competitive and rapidly changing biopharmaceutical and immuno-oncology industries. The company's focus on first-in-class treatments for various cancers, particularly with amezalpat in HCC and TPST-1495 in FAP, positions it within a high-risk, high-reward segment. The strategic review and workforce reduction reflect broader market conditions and capital constraints common in the clinical-stage biotechnology sector, where companies often seek partnerships or M&A to advance costly development programs. The receipt of Fast Track and Orphan Drug Designations for its lead candidates aligns with industry efforts to accelerate therapies for serious unmet medical needs.

Comparison to Industry Standards

• The company's cash runway of less than 12 months is below the typical industry standard for clinical-stage biotech companies, which often aim for 18-24 months of cash to fund operations and avoid frequent capital raises.
• The significant accumulated deficit of $225.84 million is common for clinical-stage biotechnology companies that have not yet commercialized products, reflecting substantial R&D investment.
• The 1-for-13 reverse stock split is a common measure taken by companies to maintain Nasdaq listing compliance, often indicating a low share price that may deter institutional investors.
• The exploration of strategic alternatives (mergers, acquisitions, partnerships) is a standard industry practice for biotech companies facing funding challenges or seeking to maximize asset value, especially for promising clinical programs like amezalpat with positive Phase 2 data and regulatory designations.
• The positive Phase 1b/2 survival data for amezalpat in HCC (six-month OS improvement, HR 0.65) is a strong clinical signal, comparable to or exceeding initial data from other successful oncology drug developments at similar stages. For example, Opdivo (nivolumab) and Yervoy (ipilimumab) combinations in HCC have shown median OS improvements, setting a high bar for new entrants.
• The Fast Track and Orphan Drug Designations for amezalpat and TPST-1495 are positive regulatory milestones, aligning with industry benchmarks for promising therapies addressing unmet medical needs. These designations are sought by many biotech firms to expedite development.
• The workforce reduction and executive transitions to consulting roles are cost-containment measures, often seen in biotech companies undergoing strategic shifts or facing liquidity constraints, similar to actions taken by other small-cap biotechs in challenging market environments.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings that would have a material adverse effect on its business, financial position, results of operations, or cash flows.

Related Party Transactions

• Success bonus agreements were entered into on August 11, 2025, with Stephen Brady (CEO), Samuel Whiting (EVP & CMO), Nicholas Maestas (CFO), and Justin Trojanowski (Corporate Controller, Treasurer, and Principal Accounting Officer) for total aggregate success bonuses of $725,000, contingent on a Change in Control prior to January 31, 2026.

Stakeholder Impact

• Shareholders: Significant dilution risk from future capital raises, potential for total loss of investment if strategic alternatives fail and operations wind down, stock price volatility, reduced liquidity due to reverse stock split, and potential anti-takeover effects from corporate governance provisions.
• Employees: Significant workforce reduction (21 of 26 full-time employees) leading to job losses, potential decrease in morale among remaining employees, and loss of institutional knowledge. Key executives transitioned to consulting roles.
• Customers/Patients: Potential delays or termination of product development efforts if additional funding is not secured, impacting the availability of new cancer treatments like amezalpat and TPST-1495.
• Creditors: The repayment of the Oxford Loan reduces debt obligations, but the going concern doubt indicates elevated risk for future creditors.
• Suppliers/Partners: Potential disruptions or changes in relationships due to the company's strategic review, financial constraints, and reliance on third-party manufacturers and CROs.

Next Steps

• Advance amezalpat into a pivotal Phase 3 study in first-line HCC patients, subject to securing additional resources.
• Explore TPST-1495 in a Phase 2 study in patients with FAP with the CP-CTNet in 2025.
• Explore strategic and business development opportunities (partnerships, licensing) to maximize pipeline potential and extend financial resources.
• Continue to implement cost reductions.
• Management (CEO, CMO, CFO) will continue to serve in their executive roles under consulting arrangements.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on financial statements and estimated effective tax rate.
• Potential payment of success bonuses to key executives if a Change in Control is consummated prior to January 31, 2026.

Key Dates

Recommendation

The company explicitly states 'substantial doubt' about its ability to continue as a going concern for the next 12 months, indicating severe financial distress. Despite positive clinical milestones for its drug candidates, the lack of sufficient funding to advance these programs, coupled with a drastic workforce reduction and executive transitions to consulting roles, points to a highly precarious financial position. The ongoing strategic review, with no guaranteed outcome, adds significant uncertainty. Investors face a high risk of substantial or total loss of investment if a viable strategic alternative or additional funding is not secured promptly. The current cash position is insufficient to sustain operations, making the stock a strong sell.

Keywords

Biotechnology, Oncology, Cancer Treatment, Clinical Stage, SEC Filing, 10-Q, Tempest Therapeutics, TPST, Amezalpat, TPST-1120, Hepatocellular Carcinoma, HCC, PPAR antagonist, TPST-1495, Familial Adenomatous Polyposis, FAP, PGE2 antagonist, Orphan Drug Designation, Fast Track Designation, Strategic Alternatives, Workforce Reduction, Going Concern, Clinical Trials, Drug Development, Financial Results